JW Pharmaceutical Corp
JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam steri… Read more
JW Pharmaceutical Corp (001067) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.132x
Based on the latest financial reports, JW Pharmaceutical Corp (001067) has a cash flow conversion efficiency ratio of 0.132x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩46.92 Billion) by net assets (₩354.10 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
JW Pharmaceutical Corp - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how JW Pharmaceutical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
JW Pharmaceutical Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of JW Pharmaceutical Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tatwah Smartech Co Ltd
SHE:002512
|
0.071x |
|
Third Coast Bancshares, Inc.
NASDAQ:TCBX
|
0.040x |
|
JSE Limited
PINK:JSEJF
|
0.117x |
|
Changshu Automotive Trim Co
SHG:603035
|
-0.004x |
|
Shenzhen Yanmade Technology Inc
SHG:688312
|
0.023x |
|
Shanghai Jinfeng Wine Co Ltd
SHG:600616
|
0.004x |
|
SCG PACKAGING -NVDR- BA1
F:5Y7
|
N/A |
|
Zhanjiang Guolian Aquatic Products
SHE:300094
|
0.014x |
Annual Cash Flow Conversion Efficiency for JW Pharmaceutical Corp (2014–2024)
The table below shows the annual cash flow conversion efficiency of JW Pharmaceutical Corp from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩329.49 Billion | ₩79.39 Billion | 0.241x | -26.62% |
| 2023-12-31 | ₩265.44 Billion | ₩87.16 Billion | 0.328x | +30.59% |
| 2022-12-31 | ₩225.76 Billion | ₩56.76 Billion | 0.251x | +161.57% |
| 2021-12-31 | ₩188.54 Billion | ₩18.12 Billion | 0.096x | -68.37% |
| 2020-12-31 | ₩207.47 Billion | ₩63.05 Billion | 0.304x | +25.93% |
| 2019-12-31 | ₩230.09 Billion | ₩55.53 Billion | 0.241x | +20.47% |
| 2018-12-31 | ₩260.11 Billion | ₩52.11 Billion | 0.200x | +62.17% |
| 2017-12-31 | ₩270.78 Billion | ₩33.45 Billion | 0.124x | +406.54% |
| 2016-12-31 | ₩276.31 Billion | ₩6.74 Billion | 0.024x | +231.67% |
| 2015-12-31 | ₩225.41 Billion | ₩-4.17 Billion | -0.019x | -155.99% |
| 2014-12-31 | ₩220.02 Billion | ₩7.28 Billion | 0.033x | -- |